Explore/

Cannabis Stocks

Cannabis Stocks

81.30k followers22 symbols Watchlist by Yahoo Finance

Follow this list to discover and track the stock of publicly traded companies with exposure to cannabis

22 symbols

To view the complete list, get the Yahoo Finance app

Get the Yahoo Finance app

  • Free real-time data
  • News and price alerts
  • Add and edit holdings
  • Track performance
  • Create multiple watchlists
  • IPO Market in General Is Quite Sensitive, Says EY’s Choi
    Bloomberg2 days ago

    IPO Market in General Is Quite Sensitive, Says EY’s Choi

    Jul.15 -- Ringo Choi, IPO leader at EY Asia Pacific, discusses the IPO market in Asia, how the listing failure of AB InBev will impact future offerings and Alibaba’s upcoming IPO. He speaks on “Bloomberg Markets: China Open.”

  • Why hard seltzer sales continue to surge in America
    Yahoo Finance14 hours ago

    Why hard seltzer sales continue to surge in America

    Cheers to surging hard seltzer sales.

  • Financial Times3 hours ago

    How the Fed chairman could give the world’s largest brewer a helping hand

    FT premium subscribers can click here to receive Due Diligence every day by email. One thing to start: on Friday next week our friends at FT Alphaville are putting on what they say is an ‘experimental theatrical journalism experience’ in London. Pamela Anderson has helped to promote the event.

  • Financial Times4 hours ago

    AB InBev’s deal machine on hold after Asia IPO flop

    For Anheuser-Busch InBev’s deal-hungry chief executive Carlos Brito, the initial public offering of its Asian business held out a beguiling prospect. The almost $10bn that the world’s biggest brewer hoped to raise would help foot some of the bill for a decade-long acquisition spree.

  • Here's Why Anheuser-Busch InBev Yanked 2019's Largest IPO
    Motley Fool6 hours ago

    Here's Why Anheuser-Busch InBev Yanked 2019's Largest IPO

    The market just didn't agree with the valuation the giant brewer tried to put on its Asia Pacific unit, Budweiser Brewing Company APAC.

  • Cronos Group (CRON) Gains As Market Dips: What You Should Know
    Zacks9 hours ago

    Cronos Group (CRON) Gains As Market Dips: What You Should Know

    Cronos Group (CRON) closed at $14.99 in the latest trading session, marking a +0.33% move from the prior day.

  • Can We Find The Right Stock Using Our Newly Found Insight?
    Zacks11 hours ago

    Can We Find The Right Stock Using Our Newly Found Insight?

    Can We Find The Right Stock Using Our Newly Found Insight?

  • Should You Buy a Cannabis ETF?
    Zacks15 hours ago

    Should You Buy a Cannabis ETF?

    There are now 3 pot ETFs with several more to launch soon. Is this a good way for investors to get exposure to the cannabis industry?

  • Should Value Investors Buy AbbVie (ABBV) Stock?
    Zacks18 hours ago

    Should Value Investors Buy AbbVie (ABBV) Stock?

    Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

  • AbbVie (ABBV) Upgraded to Buy: Here's What You Should Know
    Zacks18 hours ago

    AbbVie (ABBV) Upgraded to Buy: Here's What You Should Know

    AbbVie (ABBV) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

  • AbbVie (ABBV) is an Incredible Growth Stock: 3 Reasons Why
    Zacks18 hours ago

    AbbVie (ABBV) is an Incredible Growth Stock: 3 Reasons Why

    AbbVie (ABBV) is well positioned to outperform the market, as it exhibits above-average growth in financials.

  • 3 Puny Pot Stocks That Can Grow a Whole Lot of Weed
    Motley Fool19 hours ago

    3 Puny Pot Stocks That Can Grow a Whole Lot of Weed

    All three of these smaller marijuana stocks is capable of at least 300,000 kilos of annual cannabis output.

  • Motley Fool20 hours ago

    Canopy Growth Just Confirmed What We've Long Suspected

    Canopy CFO Mike Lee dishes on growth expectations for fiscal 2020.

  • Altria (MO) Stock Moves -0.26%: What You Should Know
    Zacks2 days ago

    Altria (MO) Stock Moves -0.26%: What You Should Know

    Altria (MO) closed the most recent trading day at $49.41, moving -0.26% from the previous trading session.

  • Canopy Growth Corporation (CGC) Gains As Market Dips: What You Should Know
    Zacks2 days ago

    Canopy Growth Corporation (CGC) Gains As Market Dips: What You Should Know

    In the latest trading session, Canopy Growth Corporation (CGC) closed at $35.56, marking a +1.11% move from the previous day.

  • The Highest-Yielding Dividend Stock in Marijuana
    Motley Fool2 days ago

    The Highest-Yielding Dividend Stock in Marijuana

    This increasingly cannabis-focused company currently yields 6.5%.

  • 3 Top Dividend Stocks With Yields Over 5%
    Motley Fool2 days ago

    3 Top Dividend Stocks With Yields Over 5%

    Just because AT&T, Shell, and Altria have high yields doesn't necessarily make them high risk.

  • AbbVie (ABBV) Acquires Mavupharma to Boost Cancer Portfolio
    Zacks2 days ago

    AbbVie (ABBV) Acquires Mavupharma to Boost Cancer Portfolio

    AbbVie (ABBV) buys Mavupharma to develop novel treatments for cancer using the latter's STING signaling pathway.

  • Zacks2 days ago

    J&J (JNJ) Beats on Q2 Earnings, Ups 2019 Sales Growth View

    J&J (JNJ) beats estimates for both earnings and sales in the second quarter of 2019 and raises 2019 guidance for operational sales growth for the second time this year.

  • Implied Volatility Surging for Canopy Growth (CGC) Stock Options
    Zacks2 days ago

    Implied Volatility Surging for Canopy Growth (CGC) Stock Options

    Investors need to pay close attention to Canopy Growth (CGC) stock based on the movements in the options market lately.

  • Cannabis Outlook From OrganiGram’s Earnings Report
    Market Realist2 days ago

    Cannabis Outlook From OrganiGram’s Earnings Report

    On Monday, OrganiGram (OGI) reported its third-quarter earnings. Following the company's earnings, we reported how it performed in the third quarter. To learn more, read OrganiGram’s Third-Quarter Earnings. Interestingly, OrganiGram stressed that the growth would be heavily driven by retail stores opening in Ontario and Quebec. The company stated that legalizing edibles and derivative products […]

  • 7 Reasons Aurora, Canopy, Cronos, and HEXO Are All At or Near 6-Month Lows
    Motley Fool2 days ago

    7 Reasons Aurora, Canopy, Cronos, and HEXO Are All At or Near 6-Month Lows

    The buzz is beginning to wear off for the most popular cannabis stocks.

  • Organigram a Canadian Pot Rarity After Four Profitable Quarters
    Bloomberg2 days ago

    Organigram a Canadian Pot Rarity After Four Profitable Quarters

    (Bloomberg) -- With four quarters of profitability under its belt, Organigram Holdings Inc. is an anomaly in the Canadian cannabis market.Organigram has higher margins than most of its peers and one of the lowest costs per gram in the industry even though it grows indoors, generally considered the most expensive method of production. Chief Executive Officer Greg Engel attributes this to its ability to get higher yields from its pot plants than companies that grow in greenhouses, as well as its automated packaging lines.“We built a facility and designed a facility that was very focused on high-quality product because we felt there was a market opportunity that was sustainable,” Engel said in an interview at Bloomberg’s Toronto office.Organigram’s streak of profitability comes as the industry undergoes a period of significant upheaval. CannTrust Holdings Inc., previously considered one of the more reputable pot companies, plunged 48% last week after Canadian regulators said it grew cannabis in unlicensed areas of its greenhouse, forcing it to halt all sales and shipments of its products.That came less than a week after Canopy Growth Corp. fired co-CEO Bruce Linton amid shrinking margins and a C$323 million net loss in its most recent quarter.Lower ValuationMoncton, New Brunswick-based Organigram, meanwhile, reported its fourth consecutive quarter on Monday of positive adjusted earnings before interest, taxes, depreciation and amortization, or Ebitda. Revenue of C$25 million ($19 million) missed estimates and gross margin fell to 50% from 60% in the previous quarter, but Eight Capital analyst Graeme Kreindler said he views this as an “isolated event” related to a temporary change in cultivation protocols and the timing of shipments to provinces.Organigram said it cost 95 cents to produce a gram of dried flower in its most recent quarter. That was up from 65 cents in the previous quarter but still compares favorably with C$1.42 at Aurora Cannabis Inc. and $1.48 at Tilray Inc.No other large Canadian pot producer has managed to post such a long string of positive Ebitda. However, although it’s one of the best-performing pure-play pot stocks this year, up 64%, its valuation as measured by its price-to-sales ratio is well below those of its largest competitors.Engel is unperturbed. “At the end of the day, the worst thing that can happen to a company is you’ve got an artificial stock price that you can’t sustain,” Engel said.Competitors also spend a lot on stock promotion, he said. This “may in the short term be helping their stock price, but I’m not sure that’s sustainable without ongoing spending,” he said.The problems at CannTrust and Canopy signal a shakeout in an industry that’s still maturing nine months after Canada legalized recreational pot. Organigram is lucky because it had its wake-up call early, said Engel.The company had to recall several lots of its medical pot in late 2016 and early 2017 after it was found to contain an unapproved pesticide. Engel, who was CEO of Tilray Inc. at the time, was hired after the recall to “make a major cultural shift,” he said.“As a result of that recall, we had monthly ongoing inspections by regulators, and historically the industry was always complaining or defensive about the inspections,” Engel said. “My approach was to embrace them. At the end of the day it’s a partnership, not an adversarial relationship.”In the interview, Engel shared his views of the nascent industry:Beverages and EdiblesOrganigram isn’t being coy about its desire for a partner that can help it develop cannabis-infused beverages, similar to Constellation Brands Inc.’s investment in Canopy, Tilray’s partnership with Anheuser-Busch InBev SA or Hexo Corp.’s joint venture with Molson Coors Brewing Co.Organigram has developed a rapid-onset technology that will allow its drinks to take effect within 10 to 15 minutes, similar to alcohol, and has also created a flavorless cannabis powder that can be added to any beverage.“We wanted to go to these negotiations offering as much as possible,” Engel said. Organigram is seeking a partner from the alcohol industry that can help it develop beverages infused with THC, the cannabis compound that gets you high. It’s also seeking a consumer packaged goods partner for drinks infused with CBD, a non-intoxicating substance that’s thought to have health and wellness properties.BiosyntheticsEngel hopes Organigram’s investment in Montreal-based Hyasynth Biologicals Inc. will also help it lure a partner. Hyasynth is developing large-scale biosynthetic production of cannabinoids, or the active compounds found in cannabis. This method, which uses yeast to produce the compounds in a lab, is cheaper than extracting them from plants and will help lower production costs for products like beverages, edibles and vape pens, said Engel.U.S. Market“We’re very actively looking at the CBD market in the U.S.,” where the substance is legal at the federal level as long as it’s derived from hemp with very low THC content, Engel said. Organigram doesn’t plan to grow its own hemp but is looking at a range of possibilities, including investments in existing brands, products and companies.Corporate GovernanceOrganigram has a fully independent board of directors, a rarity in the cannabis sector. The CEO sees good corporate governance as essential to a well-run pot company.“This is an industry that’s still very much moving from founders and executives being chairmen or multiple insiders on boards, and I think some of the challenges we’ve seen in the industry have been because of a lack of governance,” he said. “You have to have independent governance that has oversight and holds management accountable.”To contact the reporter on this story: Kristine Owram in Toronto at kowram@bloomberg.netTo contact the editors responsible for this story: Brad Olesen at bolesen3@bloomberg.net, ;David Scanlan at dscanlan@bloomberg.net, Jacqueline ThorpeFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.

  • Here's Why AB InBev (BUD) Withdraws $9.8B IPO in Hong Kong
    Zacks3 days ago

    Here's Why AB InBev (BUD) Withdraws $9.8B IPO in Hong Kong

    AB InBev (BUD) withdraws the planned $9.8-billion IPO for its Budweiser unit in Asia, which would have been the world's biggest IPO for 2019 after Uber's $8.1-billion offering.